medigraphic.com
ISSN 1561-3119 (Digital)

2012, Número 4

<< Anterior Siguiente >>

Rev Cubana Pediatr 2012; 84 (4)


Staphylococcus aureus, evolución de un viejo patógeno

Álvarez LI, Ponce BJ

Idioma: Español
Referencias bibliográficas: 40
Paginas:
Archivo PDF: 201.35 Kb.


RESUMEN

El Staphylococcus aureus está considerado uno de los microorganismos más importantes en la práctica médica diaria. Es capaz de provocar una amplia gama de enfermedades, ya sea por acción directa o mediante la acción de sus toxinas. El tratamiento de estas infecciones se ha convertido en algo extraordinariamente complejo en la época actual como consecuencia de la aparición en la comunidad de cepas de S. aureus, resistentes a la meticillina, que provocan infecciones en pacientes sin factores de riesgo, fundamentalmente niños y adolescentes. En este artículo se hace una revisión, que va desde los cambios en la epidemiología de este patógeno, hasta las implicaciones que para el tratamiento médico presupone este fenómeno.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs needs drugs: an update on the development pipeline from the antimicrobial availability task force. Clin Inf Dis. 2006;42:657-68.

  2. Gordon JG, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:350-9.

  3. Jevons, M. "Celbenin"-resistant staphylococci. BMJ. 1961;1:124-5.

  4. Hiramatsu K, Hanaki H, Ino T, Yatuba K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135-6.

  5. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb Mortal Wkly Rep. 51:565-7.

  6. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Review Microbiology. 2009;7:629-41.

  7. National Nosocomial Infectious Surveillance System (NNIS). System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-85.

  8. Diederen BM, Kluytmans JA. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect. 2006;52:157-68.

  9. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene. 2011. Estudio de prevalencia de las infecciones nosocomiales en España. EPINE 1990-2011: 22 años. 22º Estudio. Informe Global de España [monografía en Internet]; España [citado 8 de febrero de 2012]. Disponible en: http://www.vhebron.net/ac/preventiva/epine/9-epine_1990-2011.pdf

  10. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus. Minnesota and North Dakota, 1997-1999. Morb Mortl Wkly Rep. 1999;48:707-10.

  11. Saïd-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol. 2003;24:451-5.

  12. Bustos-Martínez JA, Hamdan-Partida A, Gutiérrez-Cárdenas M. Staphylococcus aureus: la reemergencia de un patógeno en la comunidad. Rev Biomed. 2006;17:287-305.

  13. Broseta A, Chaves F, Rojo P, Otero JR. Emergencia de un clon de Staphylococcus aureus resistente a meticilina de origen comunitario en la población pediátrica del sur de Madrid. Enferm Infecc Microbiol Clin. 2006;24:31-5.

  14. Hisata K, Kuwahara-Arai K, Yamanoto M, Ito T, Nakatomi Y, Cui L, et al. Dissemination of methicillin-resistant staphylococci among healthy japanese children. J Clin Microbiol. 2005;43:3364-72.

  15. Vourli S, Perimeni D, Makri A, Polemis M, Voyiatzi A, Vatopoulos A. Community acquired MRSA infections in a paediatric population in Greece. Euro Surveill. 2005;10:78-9.

  16. Wylie JL, Nowicki DL. Molecular epidemiology of community and health care-associated methicillin-resistant Staphylococcus aureus in Manitoba, Canada. J Clin Microbiol. 2005;43:2830-6.

  17. Aramburu C, Harbarth S, Liassine N, Girard M, Gervaix A, Scherenzei J. Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland: first surveillance report. Euro Surveill. 2006;11:42-3.

  18. Ribeiro A, Dias C, Silva-Carvalho MC, Berquó L, Ferreira FA, Soares Santos RN, et al. First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol. 2005;43:1985-8.

  19. Vandenesch F, Naimi T, Enrigth MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant. Staphylococcus aureus carrying Panton-Valentine leukocidin genes: world emergence. Emerg Infect Dis. 2003;9:978-84.

  20. Lina G, Piémont Y, Godail-Gamont F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine Leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128-32.

  21. Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicro Agents Chemother. 2002;46:1147-52.

  22. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemoter. 2004;48:2637-51.

  23. Zhang K, McClure JA, Elsayed S, Conly JM. Novel staphylococcal cassette chromosome mec type, tentatively designated type VIII, harbouring class A mec and type 4 ccr gene complexes in Canadian epidemic strain of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:531-40.

  24. Panton P, Valentine F. Staphylococcal toxins. Lancet. 1932;222:506-8.

  25. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med. 2007;13:1510-4.

  26. Konig B, Prevost G, Piemont Y, Konig W. Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis. 1995;171:607-13.

  27. Aires de Sousa M, de Lencastre H. Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant Staphylococcus aureus clones. FEMS Immunol Med Microbiol. 2004;40:101-11.

  28. Cruz C, Moreno J, Renzoni A, Hidalgo M, Reyes J, Schrenzel J, et al. Tracking methicillin-resistant Staphylococcus aureus clones in Colombian hospitals over 7 years (1996-2003): emergence of a new dominant clone. Int J Antimicrob Agents. 2005;26:457-62.

  29. Ribeiro A, Dias C, Silva-Carvalho MC, Buquol L, Ferreira FA, Santos RN, et al. First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol. 2005;43:1985-8.

  30. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergency of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309-17.

  31. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet. 2006;367:731-9.

  32. David MZ, Rudolph KM, Hennessy TW, Boyle-Vavra S, Daum RS. Molecular epidemiology of methicillin-resistant Staphylococcus aureus. Lancet. 2006;367:731-9.

  33. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus. Infections in Adults and Children. Clinical Practice Guidelines. CID. 2011;52:1-38.

  34. Mensa J, Barberán J, Llenares P, Picazo JJ, Bouza E, Alvarez Lerma F, et al. Guía de tratamiento de la infección producida por Staphylococcus aureus resintente a la meticilina. Rev Esp Quimioter. 2008;21(4):234-8.

  35. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004;30:388-94.

  36. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteremia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923-9.

  37. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatric Infect Dis J. 2006;25(6):562-4.

  38. Fritsche TR, Rennie RP, Goldstein BP, Jones RN. Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and referencedilution methods using gram-positive organisms. J Clin Microbiol. 2006;44(8):2988-90.

  39. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40(7):1058-60.

  40. Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, et al. In vitro activity of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillinresistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother. 2006;50(8):2680-5.




2020     |     www.medigraphic.com